1. Zhongguo Fei Ai Za Zhi. 2022 Jul 20;25(7):487-492. doi: 
10.3779/j.issn.1009-3419.2022.101.38.

[Application of MIDD in Clinical Research of Antitumor Drugs].

[Article in Chinese; Abstract available in Chinese from the publisher]

Yu M(1), Wang H(1).

Author information:
(1)Clinical Pharmacology Research Center, Peking Union Medical College Hospital, 
 Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 
100730, China.

The antitumor drug has become one of the focused areas in new drug research and 
development. Their clinical research generally consumes a long period of time, 
with high cost and high risk. Model-informed drug development (MIDD) integrates 
and quantitatively analyzes physiological, pharmacological, and disease 
progression information through modeling and simulation, which can reduce the 
cost of drug development and improve the efficiency of clinical research. In 
this essay, Osimertinib and Pembrolizumab are given as examples to illustrate 
the specific application of MIDD in different phases of clinical research, 
aiming to provide references for the application of MIDD to guide the clinical 
research of antitumor drugs. .

Publisher: 【中文题目：浅析MIDD在抗肿瘤药物临床研究中的应用】 
【中文摘要：抗肿瘤药物是新药研发的热点方向，其临床研究具有研发周期长、研发成本和风险高的特点。模型引导的药物开发（model-informed drug 
development, 
MIDD）通过建模与模拟，能够对生理学、药理学以及疾病进程等信息进行整合和定量分析，降低药物研发成本，提高临床研究效率。本文以奥希替尼和帕博利珠单抗为例，以问题为导向，阐述MIDD在抗肿瘤药物临床研究各个阶段的具体应用，旨在为MIDD指导抗肿瘤临药物床研究提供一定的借鉴和参考。 】 
【中文关键词：模型引导的药物开发；暴露量-效应关系；群体药代动力学；奥希替尼；帕博利珠单抗】.

DOI: 10.3779/j.issn.1009-3419.2022.101.38
PMCID: PMC9346158
PMID: 35899446 [Indexed for MEDLINE]